Britannia Life Sciences Inc.
BLSIF
$0.04
$0.000.00%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -52.79% | 7.82% | -- | -6.72% | -88.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -52.79% | 7.82% | -- | -6.72% | -88.88% |
| Cost of Revenue | -7.48% | 146.51% | -- | 16.74% | -87.03% |
| Gross Profit | -75.55% | -71.65% | -- | -18.46% | -89.62% |
| SG&A Expenses | 105.78% | -11.20% | -- | -2.00% | -71.01% |
| Depreciation & Amortization | 4.55% | 5.61% | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 82.18% | 7.58% | -- | 4.36% | -75.56% |
| Operating Income | -236.16% | -7.47% | -- | -602.88% | -166.65% |
| Income Before Tax | 71.55% | 25.05% | -- | -108.66% | -257.58% |
| Income Tax Expenses | -- | -- | -- | 19.13% | -- |
| Earnings from Continuing Operations | 71.55% | 25.05% | -- | -128.00% | -286.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -119.84% | -247.26% |
| Net Income | 65.91% | 7.42% | -- | -124.85% | -262.22% |
| EBIT | -236.16% | -7.47% | -- | -602.88% | -166.65% |
| EBITDA | -254.47% | -7.55% | -- | -238.49% | -150.09% |
| EPS Basic | 66.67% | 6.06% | 97.78% | -125.00% | -263.64% |
| Normalized Basic EPS | 68.75% | -127.59% | -- | -233.33% | -300.00% |
| EPS Diluted | 66.67% | 6.06% | 97.78% | -125.00% | -263.64% |
| Normalized Diluted EPS | 68.75% | -127.59% | -- | -233.33% | -300.00% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |